Could coenzyme QIO and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA?
Dear Sir, Maternally-inherited "diabetes and deafness syndrome" has been related to a point mutation of mtDNA leading to an A to G transition at position 3243 in the tRNA leucine gene [1] [2] [3] [4] [5] [6] [7] [8] [9] . This mutation has been previously observed in patients with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). In this disease, as in other mitochondrial myopathies, treatment by coenzyme Q10 has been shown to dramatically improve muscle oxidative metabolism in some patients [10] [11] [12] [13] [14] . We wondered whether coenzyme Q 10 or related compounds which improve mitochondrial oxidative processes might be useful in the treatment of this type of diabetes. Accordingly, we treated a diabetic patient who exhibited the 3243 mutation with a combination of coenzyme Q10 (150 mg/day) and L-carnitine (2 g/day) for 6 months in order to evaluate whether improvement of glucose tolerance as well as muscle oxidative functions could be observed. The patient was a 49-year-old woman who had a 3243 mutation in the tRNA leucine gene identified with a combination of maternally-inherited diabetes, deafness and atypical pigmentary retinitis. Non-insulin-dependent diabetes was diagnosed at the age of 25 years and insulin treatment had to be introduced at the age of 40 years after oral hypoglycaemic agent failure. Of the total mtDNA, 11% of that in blood cells and 74 % of that in muscle was found to be mutated. Muscle impairment had been diagnosed by pathology and 31p nuclear magnetic resonance spectroscopy. The 31p magnetic resonance spectroscopy data were recorded throughout a standardized rest-exercise-recovery protocol as previously described [15] . Low residual insulin secretion was assessed by C- The effect of the treatment on glucose tolerance at 3 and 6 months is summarized in Table 1 . During coenzyme Q10 and L-carnitine administration metabolic post-stimulative Cpeptide values did not change. In contrast, at the muscular level the patient felt better and 31p NMR spectroscopy showed an improvement in oxidative metabolism. Metabolic changes were recorded before and after 3 months of treatment. Decreased phosphocreatine/inorganic phosphate (PCr/Pi) ratio measured at rest, before treatment, indicated an impaired muscle energy state, while after palliative therapy, normalization of the value reflected the improvement of oxidative metabolism. Similarly, ADP concentration, calculated from the creatine kinase equilibrium, returned to normal after treatment (35.68 vs 9.87 ~mol/1). During the 3-rain exercise of the forearm flexor muscles, glycolysis-induced pH decrease was large (6.23) compared to the pre-treatment value (6.63) whereas a trend towards a iimitation of the PCr breakdown (20.98 vs 15.36 mmol/1) was observed. Kinetics of PCr/Pi recovery, closely associated with the mitochondrial function, was slower than normal before treatment, as a manifestation of oxidative impairment. Taking into account the effect of end-of-exercise pH on recovery processes [16] , the PCr/Pi kinetics returned to normal upon treatment, further confirming the positive effect of coenzyme Q palliative therapy upon muscular oxidative metabolism. Finally, the clinical tolerance was fair; the patient complained only of moderate itching, which did not lead her to drop out of the study. These results show that short-term treatment with coenzyme Q10 and L-carnitine, while acting on mitochondrial muscle functions, were unable to restore insulin secretion and/or insulin sensitivity in our patient. This discrepancy in effectiveness of the treatment on these two tissues suggests that the impairment of muscle oxidative processes is probably not involved in the glucose intolerance in this disease. This therapeutic failure, however does not definitely mean that coenzyme Q10 is not of potential benefit in the management of diabetes secondary to mitochondriopathy. It is possible that pancreatic beta cells are less sensitive and in need of a higher dosage of coenzyme Q10 for a longer duration in order to improve mitochondrial functions. In addition, we can hypothesize that treatment was introduced too late in the natural course of the disease. Katagiri et al. [4] have shown that there is a progressive loss of insulin secretion in some subjects with the 3243 mutation. The insulin secretion in our patient was reduced to levels usually observed in classic insulin-dependent diabetes, suggesting that there was a profound loss of beta cells. It is probable that treatment applied at earlier stages, such as during either glucose intolerance or non-insulin-dependent diabetes, may improve insulin production. Because these drugs are well tolerated and their beneficial effect on other tissues such as muscle suggest extending such a clinical trial to patients with less severe pancreatic lesions. 
